Velox LB is a vascular closure device that leverages and improves on technology from velox CD™ for large bore (12-18 Fr) percutaneous procedures such as TAVR and EVAR. The implant is fabricated from a proprietary absorbable magnesium alloy that allows for the fast absorption and uncrompromised femoral perfusion.
Transluminal has completed the First-in-Man clinical study
with 100% Procedural Success.
Time to Hemostasis (TTH): 3.1 ± 3.1 min
and was 2.4 ± 2.4 min in patients with device success (9/10).
Time to Ambulation (TTA): Nine out of ten patients were allowed to get out of bed
at 2.0 ± 0.3 hr post procedure.
For investigational use only
Transluminal Technologies completes the First in-Man study of the velox LB vascular closure device
Asuncion, Paraguay, April, 2017